EA201290519A1 - Положительные аллостерические модуляторы рецептора хинолин амида m1 - Google Patents

Положительные аллостерические модуляторы рецептора хинолин амида m1

Info

Publication number
EA201290519A1
EA201290519A1 EA201290519A EA201290519A EA201290519A1 EA 201290519 A1 EA201290519 A1 EA 201290519A1 EA 201290519 A EA201290519 A EA 201290519A EA 201290519 A EA201290519 A EA 201290519A EA 201290519 A1 EA201290519 A1 EA 201290519A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
positive allosteric
allosteric modulators
amida
quinolin
Prior art date
Application number
EA201290519A
Other languages
English (en)
Other versions
EA022494B1 (ru
Inventor
Скотт Д. Кудук
Келли-Анн Шлегель
Чжи-Цян Ян
Original Assignee
Мерк Шарп Энд Домэ Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп Энд Домэ Корп. filed Critical Мерк Шарп Энд Домэ Корп.
Publication of EA201290519A1 publication Critical patent/EA201290519A1/ru
Publication of EA022494B1 publication Critical patent/EA022494B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к соединениям хинолин амида формулы (I)которые являются положительными аллостерическими модуляторами рецептора M1 и могут быть использованы в лечении заболеваний, в которых участвует рецептор M1, таких как болезнь Альцгеймера, шизофрения, боль или расстройства сна. Изобретение также относится к фармацевтическим композициям, включающим эти соединения, и к применению соединений и композиций в лечении заболеваний, опосредуемых рецептором M1.
EA201290519A 2009-12-17 2010-12-13 Соединения хинолинамида в качестве положительных аллостерических модуляторов мускаринового рецептора m1 EA022494B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28753509P 2009-12-17 2009-12-17
PCT/US2010/060007 WO2011084368A1 (en) 2009-12-17 2010-12-13 Quinoline amide m1 receptor positive allosteric modulators

Publications (2)

Publication Number Publication Date
EA201290519A1 true EA201290519A1 (ru) 2013-01-30
EA022494B1 EA022494B1 (ru) 2016-01-29

Family

ID=44305688

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290519A EA022494B1 (ru) 2009-12-17 2010-12-13 Соединения хинолинамида в качестве положительных аллостерических модуляторов мускаринового рецептора m1

Country Status (41)

Country Link
US (2) US9199939B2 (ru)
EP (1) EP2512243B1 (ru)
JP (1) JP5651708B2 (ru)
KR (1) KR101494059B1 (ru)
CN (1) CN102651970B (ru)
AR (1) AR079510A1 (ru)
AU (1) AU2010340142B2 (ru)
BR (1) BR112012014180A2 (ru)
CA (1) CA2782347C (ru)
CL (1) CL2012001605A1 (ru)
CO (1) CO6551729A2 (ru)
CR (1) CR20120327A (ru)
CY (1) CY1117726T1 (ru)
DK (1) DK2512243T3 (ru)
DO (1) DOP2012000167A (ru)
EA (1) EA022494B1 (ru)
EC (1) ECSP12011983A (ru)
ES (1) ES2575154T3 (ru)
GE (1) GEP201606506B (ru)
GT (1) GT201200201A (ru)
HK (1) HK1170122A1 (ru)
HN (1) HN2012001265A (ru)
HR (1) HRP20160574T1 (ru)
HU (1) HUE029734T2 (ru)
IL (1) IL220130A0 (ru)
MA (1) MA33920B1 (ru)
ME (1) ME02421B (ru)
MX (1) MX336774B (ru)
NI (1) NI201200107A (ru)
NZ (1) NZ600674A (ru)
PE (1) PE20121613A1 (ru)
PL (1) PL2512243T3 (ru)
PT (1) PT2512243E (ru)
RS (1) RS54798B1 (ru)
SG (1) SG181719A1 (ru)
SI (1) SI2512243T1 (ru)
TN (1) TN2012000231A1 (ru)
TW (1) TWI412525B (ru)
UA (1) UA106406C2 (ru)
WO (1) WO2011084368A1 (ru)
ZA (1) ZA201204313B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SG10201811584RA (en) * 2010-02-11 2019-01-30 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
EP2571874B1 (en) 2010-05-17 2016-03-30 Forum Pharmaceuticals Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
EP2582676B1 (en) * 2010-06-15 2016-12-14 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
US8940765B2 (en) * 2011-05-17 2015-01-27 Merck Sharp & Dohme Corp. N-linked quinolineamide M1 receptor positive allosteric modulators
US9403802B2 (en) 2012-03-02 2016-08-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use therefor
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
JP6211530B2 (ja) 2012-11-19 2017-10-11 武田薬品工業株式会社 含窒素複素環化合物
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
BR112016006154A2 (pt) * 2013-09-27 2017-08-01 Hoffmann La Roche derivados de indol e indazol
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
JP6271758B2 (ja) * 2014-01-22 2018-01-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ フルオロ−ナフチル誘導体
EP3156397B1 (en) 2014-06-13 2019-08-07 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
CN107949562B (zh) 2015-06-09 2021-07-23 拜耳制药股份公司 毒蕈碱性m2受体的正性变构调节剂
EP3347349B1 (en) * 2015-09-10 2019-09-18 Suven Life Sciences Limited Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
WO2017099969A1 (en) * 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Tetrahydroquinoxaline m1 receptor positive allosteric modulators
KR20180110132A (ko) 2016-02-16 2018-10-08 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제
WO2017151449A1 (en) * 2016-03-04 2017-09-08 Merck Sharp & Dohme Corp. M1 receptor positive allosteric modulator compounds and methods of use thereof
WO2018011017A1 (de) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung
CA3034775C (en) 2016-09-02 2020-07-14 Suven Life Sciences Limited Muscarinic m1 receptor positive allosteric modulators
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
US10899759B2 (en) 2016-09-30 2021-01-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
DK3643718T3 (da) * 2017-06-20 2023-11-06 Takeda Pharmaceuticals Co Heterocyklisk forbindelse og anvendelse deraf som positiv allosterisk modulator af den kolinerge muskarin m1-receptor
EP3643718B1 (en) * 2017-06-20 2023-07-26 Takeda Pharmaceutical Company Limited Heterocyclic compound and its use as positive allosteric modulator of the cholinergic muscarinic m1 receptor.
KR102406885B1 (ko) * 2017-10-27 2022-06-08 수벤 라이프 사이언시스 리미티드 무스카린 m1 수용체 양성 알로스테릭 조절제로서 다환형 아미드
EP3858828A4 (en) 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
US20220041581A1 (en) 2018-09-28 2022-02-10 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
BR112021007168A2 (pt) 2018-10-17 2021-08-10 Suven Life Sciences Limited derivados de pirrolo-piridazina como moduladores alostericos positivos do receptor muscarínico m1
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
EP1314726A4 (en) 2000-08-29 2005-07-13 Yamanouchi Pharma Co Ltd NEW ESTER OR AMID DERIVATIVES
WO2004073639A2 (en) 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
WO2004080463A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
ATE457309T1 (de) * 2003-12-23 2010-02-15 Serodus As Modulatoren von peripheren 5-ht-rezeptoren
EP1725240A4 (en) * 2004-03-17 2009-03-25 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
CN101321733A (zh) * 2005-12-05 2008-12-10 默克公司 喹诺酮m1受体阳性变构调节剂
WO2007100366A2 (en) * 2005-12-05 2007-09-07 Merck & Co., Inc. Quinolone m1 receptor positive allosteric modulators
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
CA2716921A1 (en) * 2008-03-21 2009-09-24 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
PL2358686T3 (pl) 2008-11-20 2013-02-28 Merck Sharp & Dohme Arylometylobenzochinazolinonowe dodatnie modulatory allostertyczne receptora M1
CA2750708A1 (en) 2009-02-23 2010-08-26 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators
US8293744B2 (en) 2009-04-20 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
RU2507204C2 (ru) 2009-08-31 2014-02-20 Мерк Шарп И Доум Корп. Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона
US8895580B2 (en) 2009-10-21 2014-11-25 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone M1 receptor positive allosteric modulators
WO2011062853A1 (en) 2009-11-20 2011-05-26 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
US8664387B2 (en) 2009-12-14 2014-03-04 Merck Sharp & Dohme Corp. Pyridoquinazolinone M1 receptor positive allosteric modulators
EP2515656B1 (en) 2009-12-21 2014-08-06 Merck Sharp & Dohme Corp. Aminobenzoquinazolinone m1 receptor positive allosteric modulators
EP2575454B1 (en) 2010-05-28 2018-08-29 Merck Sharp & Dohme Corp. Naphthalene carboxamide m1 receptor positive allosteric modulators
EP2582676B1 (en) 2010-06-15 2016-12-14 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
US8557992B2 (en) 2010-06-15 2013-10-15 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators
US8940765B2 (en) 2011-05-17 2015-01-27 Merck Sharp & Dohme Corp. N-linked quinolineamide M1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
IL220130A0 (en) 2012-07-31
GT201200201A (es) 2015-05-20
TWI412525B (zh) 2013-10-21
AU2010340142B2 (en) 2014-05-08
TW201130824A (en) 2011-09-16
CY1117726T1 (el) 2017-05-17
PL2512243T3 (pl) 2016-09-30
US20120252808A1 (en) 2012-10-04
US20160075656A1 (en) 2016-03-17
CN102651970A (zh) 2012-08-29
WO2011084368A1 (en) 2011-07-14
ZA201204313B (en) 2016-01-27
TN2012000231A1 (en) 2013-12-12
UA106406C2 (ru) 2014-08-26
CN102651970B (zh) 2014-11-12
CR20120327A (es) 2012-07-30
MA33920B1 (fr) 2013-01-02
AU2010340142A1 (en) 2012-06-14
NZ600674A (en) 2013-05-31
PE20121613A1 (es) 2012-12-02
CA2782347C (en) 2014-09-23
ME02421B (me) 2016-09-20
MX2012007013A (es) 2012-07-03
US9199939B2 (en) 2015-12-01
EP2512243B1 (en) 2016-04-06
HRP20160574T1 (hr) 2016-06-17
HUE029734T2 (en) 2017-03-28
KR101494059B1 (ko) 2015-02-16
HN2012001265A (es) 2015-09-07
JP2013514358A (ja) 2013-04-25
CA2782347A1 (en) 2011-07-14
EP2512243A4 (en) 2013-05-29
AR079510A1 (es) 2012-02-01
PT2512243E (pt) 2016-06-08
BR112012014180A2 (pt) 2015-09-15
SG181719A1 (en) 2012-07-30
NI201200107A (es) 2012-10-30
DK2512243T3 (en) 2016-07-25
HK1170122A1 (zh) 2013-02-22
RS54798B1 (sr) 2016-10-31
EA022494B1 (ru) 2016-01-29
CL2012001605A1 (es) 2012-10-05
GEP201606506B (en) 2016-07-11
JP5651708B2 (ja) 2015-01-14
KR20120084324A (ko) 2012-07-27
EP2512243A1 (en) 2012-10-24
CO6551729A2 (es) 2012-10-31
SI2512243T1 (sl) 2016-07-29
DOP2012000167A (es) 2012-12-31
ES2575154T3 (es) 2016-06-24
MX336774B (es) 2016-01-28
ECSP12011983A (es) 2012-07-31

Similar Documents

Publication Publication Date Title
EA201290519A1 (ru) Положительные аллостерические модуляторы рецептора хинолин амида m1
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
EA201170705A1 (ru) Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
ATE475650T1 (de) Positive allosterische chinolon-m1- rezeptormodulatoren
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
MX2009011364A (es) Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2-il) y n-(5-heteroarilcroman-3-il)carboxamida para el tratamiento del dolor.
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
IN2014KN01075A (ru)
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
ATE555116T1 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
MX2013002119A (es) Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3.
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
JO2919B1 (en) Aryl methyl benzocoinazolinone M1 positive allosteric modulation receptor
EA201270825A1 (ru) Применение производного эстрогена для производства фармацевтических композиций, пригодных для лечения и/или предотвращения психиатрических заболеваний, и для лечения и предотвращения указанных заболеваний

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU